^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mefatinib (MET306)

    i
    Other names: MET306, MET-306
    Company:
    Huadong Medicine
    Drug class:
    EGFR inhibitor, HER2 inhibitor
    Related drugs:
    over1year
    A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. (PubMed, Cancer Commun (Lond))
    No abstract available
    P2 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    mefatinib (MET306)
    over2years
    Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations. (ASCO 2022)
    Mefatinib has shown promising anti-tumor activity and a favorable safety profile in patients with advanced NSCLC harboring rare EGFR mutations.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    mefatinib (MET306)